IO Biotech’s IO102 + IO103 Receive the US FDA’s Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma

 IO Biotech’s IO102 + IO103 Receive the US FDA’s Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma

IO Biotech’s IO102 + IO103 Receive the US FDA’s Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma

Shots:

  • The BTD is based on P-I/II MM1636 study assessing IO102-IO103 (q2w, until 12wks. and thereafter q4w up to 1yr.) in combination with anti-PD-1 Ab, as a 1L treatment for metastatic melanoma
  • The combination of IO102 and IO103 vaccines and nivolumab demonstrated encouraging early efficacy data; ORR (79%) was reached with CR (45%) or complete disappearance of their tumors
  • IO102 and IO103 are first-in-class, immune modulatory vaccines designed to engage and activate IDO and PD-L1 specific human T-cells

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post